Background: Various methods are available to measure serum cholesterol concentrations. Of these, the cholesterol ester hydrolase (CEH)-cholesterol oxidase-peroxidase chromogenic method is widely used. However, this method has the disadvantage of interference by reducing substances. We developed and evaluated an endpoint assay for serum cholesterol, based on a CEHcholesterol dehydrogenase (CDH)-ultraviolet method. Methods: Cholesterol esters are first hydrolyzed to free cholesterol by CEH. The free cholesterol is then reduced by CDH to cholest-4-ene-3-one with the simultaneous production of ␤-NADH from ␤-NAD ؉ . At equilibrium, the CDH reaction gives incomplete conversion of cholesterol to cholest-4-ene-3-one. To overcome this disadvantage, we added hydrazine monohydrate to the reaction mixture to remove cholest-4-ene-3-one, which allowed the reaction to proceed to completion and gave stoichiometric production of ␤-NADH from the reaction of ␤-NAD ؉ with cholesterol. Results: We tested whether the amount of cholesterol added was equivalent to the absorbance change of NADH at 340 nm with six aqueous samples. Recoveries were 97.1-100.3%. The reaction was linear up to 20.28 mmol/L. The mean within-day (n ‫؍‬ 20) and betweenday (n ‫؍‬ 10) imprecision (CV) was 0.29 -0.43% and 0.22-0.61%, respectively. No interference by bilirubin, hemoglobin, ascorbic acid, and other reducing agents was observed. The equation obtained in comparison with the modified Abell-Levy-Brodie-Kendall method was: y ‫؍‬ 0.992x ؊ 0.0058 mmol/L; r ‫؍‬ 0.997; S yͦx ‫؍‬ 0.117 mmol/L; n ‫؍‬ 50.
Various methods have been devised to measure cholesterol in serum. The Abell-Levy-Brodie-Kendall (ALBK) 1 saponification method (1, 2 ) is a precise method, but it is not applicable to many kinds of samples and is difficult to automate. The cholesterol ester hydrolase-cholesterol oxidase-peroxidase (CEH-CO-POD) chromogenic method of Allain et al. (3 ) is widely used in clinical laboratories but is subject to interferences from reducing agents such as ascorbic acid, bilirubin, and reduced glutathione (4 ) . Enzymatic procedures using NAD(P ϩ )-specific cholesterol dehydrogenase (CDH) instead of CO have been described (5, 6 ) , but to date, application of these methods in an analytical setting has been limited.
Here we report a new enzymatic cholesterol assay that uses CDH from Nocardia sp. (7, 8 ) . At equilibrium, the CDH reaction gives incomplete conversion of cholesterol to cholest-4-ene-3-one. To overcome this disadvantage, we added hydrazine monohydrate to the reaction mixture to remove cholest-4-ene-3-one, which allowed the reaction to proceed to completion and gave stoichiometric production of ␤-NADH from the reaction of ␤-NAD ϩ with cholesterol. The reaction sequence is shown in Fig. 1 . The data presented suggest that the method is accurate, simple, and amenable to automation. Department of Clinical Chemistry, National Cardiovascular Center Hospital 5-7-1, Fujishirodai, Suita, Osaka 5658565, Japan.
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Materials and Methods reagents
CEH (EC3.1.1.13; Pseudomonas sp.) and CDH (Nocardia sp.) were obtained from Amano Pharmaceutical. Hemoglobin was prepared from lysed human erythrocytes. Intralipid was obtained from Kabi Pharmacia AB. Tris, "Preciset" cholesterol, and Preciset glucose were from Boehringer Mannheim. NAD ϩ and lactate dehydrogenase were from Oriental Yeast Co. Hydrazine monohydrate, Triton X-100, HEPES buffer, the chemicals used in the interference study except Intralipid and ditaurobilirubin, control sera (Wako-liquid I and II), reagent kit "Glucose Wako", and reagent kit "L-type Wako cholesterol", and all other ALBK chemicals were from Wako Pure Chemical Industries. Ditaurobilirubin, a chemically synthesized bilirubin conjugate, "High Level Check Lipid" (lyophilized serum), and "Cholesterol Calibrator" were from International Reagents. Standard Reference Material No. 911a was obtained from NIST. samples Blood samples were collected without anticoagulant from hospitalized patients. This study was approved by the committee for ethical standards of the National Cardiovascular Center Hospital.
instruments
We used a TBA-80FR⅐NEO biochemical analyzer (Toshiba) for the present assay and the other enzymatic assays in our comparison study. For optimization studies, we used a Shimadzu UV-2100 spectrophotometer with a constant temperature cell holder.
procedures
Optimization studies were performed for each of the components of the cholesterol assay. A human serum pool and/or commercial control serum were used in the optimization studies. When we had ascertained the optimum concentration of a particular ingredient, it was maintained at that concentration while the next ingredient was optimized. For manual testing of the CDH reaction, 2.00 mL of reagent 1 and 0.06 mL of specimen were pipetted into the cuvette. The mixture was preincubated at 37°for 5 min, and the absorbance was read at 340 nm. The reaction was started by the addition of 0.7 mL of reagent 2 and incubated at 37°C. After 10 min, the absorbance was again measured at 340 nm. For the blank, the same volume of reagent 2 without CDH was used. The cholesterol concentration was calculated from the change in absorbance for the standard and the sample after subtraction of the blank reading. The molar absorption coefficient of ␤-NADH at 340 nm was calculated as 6.22 ϫ 10 3 L ⅐ mol Ϫ1 ⅐ cm Ϫ1 , with the Glucose Wako reagent kit (glucokinase-glucose-6-phosphate dehydrogenase-ultraviolet method with Preciset glucose as samples) (9 ) .
In the automated CDH assay for total cholesterol, 8 L of serum was incubated with 270 L of reagent 1 for 5 min at 37°C, and the absorbance at 340/572 nm was measured. The reaction was started immediately by the addition of 90 L of reagent 2. After 4 min, the absorbance at 340/572 nm was again measured. The cholesterol concentrations of samples were determined from a calibration curve constructed with Cholesterol Calibrator and/or a factor calculated from the measured molar absorptivity of the reaction product, ␤-NADH (10 ) . For comparison studies, we determined total cholesterol concentrations by the modified ALBK method (2 ) and by the CEH-CO-POD-Nethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (DAOS) method, using a TBA-80FR⅐NEO biochemical analyzer according to the manufacturer's instructions.
statistical analysis
The mean, SD, and CV were calculated using Microsoft Excel 97 (Microsoft). Linear regression analysis by the least-squares method was performed using the StatView ® statistics program (Abacus Concepts).
Results optimization
Optimization curves for several components are shown in Fig. 2 . In the assay, we used a two-reagent system, reagents 1 and 2, with the following compositions. Reagent 1 contained 71.4 mmol/L Tris-HCl (pH 8.0), 4.3 mmol/L NAD ϩ , 1.4 kU/L CEH, 80 mmol/L hydrazine monohydrate, 1 g/L bovine serum albumin, 3 g/L sodium cholate, and 5 mL/L Triton X-100. Reagent 2 contained 14.3 mmol/L HEPES (pH 7.5), 4.3 kU/L CDH, 1 g/L bovine serum albumin, 3 g/L sodium cholate, and 5 mL/L Triton X-100.
The addition of hydrazine monohydrate (Ն30 mmol/L) to reagent 1 drove the CDH reaction to completion over a pH range of 7.6 -9.0. The reaction at pH 7.3 showed incomplete conversion of cholesterol to cholest-4-ene-3-one. In contrast, the reaction in the absence of hydrazine did not progress quantitatively at any pH. The 5 mL/L Triton X-100 was incorporated as an activator for both CEH and CDH. The 3 g/L sodium cholate was used as an additional activator of CEH. The 1 g/L bovine serum albumin was added to reagents 1 and 2 as a stabilizer. For reagent 2, pH 7.5 was selected to avoid loss of CDH. The final pH in the reaction mixture was 8.0, which was optimal for overall reaction. Reagents 1 and 2 were stable for at least 2 weeks at 2-8°C.
cdh reaction
To assess whether the CDH reaction in a complete reagent that includes CEH can progress to completion, we determined whether the amount of cholesterol added was equivalent to the expected absorbance change of ␤-NADH samples reached plateau within 3 min. Based on these results, we used the change in absorbance between 4 and 5 min after the addition of reagent 2 to assay cholesterol with the TBA-80FR⅐NEO analyzer.
Linearity studies. The linearity of the assay was evaluated by preparing sequential dilutions of High Level Check Lipid (20.28 mmol/L cholesterol) and a human serum pool (5.32 mmol/L cholesterol). Both low and high cholesterol concentrations gave a linear response, which was fitted to the following linear regression equations (95% confidence intervals in parentheses): y ϭ 0.533 (0.531-0.535) x Ϫ 0.014 (Ϫ0.028 to 0.00036) mmol/L; r ϭ 0.999; S y͉x ϭ 0.0091 mmol/L for the low cholesterol concentration; and y ϭ 2.02 (1.98 -2.06) x ϩ 0.287 (0.063-0.511) mmol/L; r ϭ 0.999; S y͉x ϭ 0.142 mmol/L for the high cholesterol concentration (Fig. 4) .
Imprecision. Within-and between-day imprecision was determined by performing measurements on two commercial control sera (Wako-liquid) and one pooled serum. Between-day testing was carried out on 10 days over a 2-week period. Calibration was performed each testing day. The within-and between-day imprecision (CV), as determined by replicate analyses of two commercial control sera (n ϭ 20) and one pooled serum (n ϭ 10) with different cholesterol concentrations, was 0.29 -0.43% and 0.22-0.61%, respectively ( Table 1) .
Interfering substances. We evaluated the effect of several potential interfering substances in this method. Bilirubin dissolved with 0.1 mol/L NaOH, ascorbate dissolved with 10 mmol/L glycine-HCl buffer (pH 3.0), lactate dehydrogenase diluted with physiological saline, and other interferents dissolved with deionized water were added to pooled serum (1:9, by volume). Each sample was measured in 10 replicate analyses. As shown in Table 2 , we found that interference Ն0.08 mmol/L cholesterol resulted from the addition of any of these substances to a serum pool. Hemoglobin at 0.31 mmol/L positively interfered, adding 0.12 mmol/L cholesterol at the upper 95% confidence limit. However, this hemoglobin concentration occurs rarely in physiological samples.
Intermethod comparison data. Fifty samples (mean Ϯ SD triglyceride concentration, 18.83 Ϯ 15.61 mmol/L) were assayed by a modified ALBK method and the automated enzymatic color test method (Fig. 5) . The values obtained in comparison with the modified ALBK method were fitted to a linear regression model using a least-squares method. The equation for the CEH-CDH method compared with the ALBK method was: y ϭ 0.992x Ϫ 0.0058 mmol/L, where x is the mean Ϯ SD ALBK cholesterol concentration (5.50 Ϯ 1.49 mmol/L); r ϭ 0.997; S y͉x ϭ 0.117 mmol/L; slope ϭ 0.992 (95% confidence interval, 0.969 -1.014); intercept ϭ Ϫ0.0058 (95% confidence interval, Ϫ0.134 to 0.123). In this comparison, y ϭ 5.45 Ϯ 1.49 mmol/L (mean Ϯ SD cholesterol concentration). The equation for the CEH-CDH method compared with the CEH-CO-POD-DAOS method was: y ϭ 0.989x Ϫ 0.048 mmol/L, where x is the mean Ϯ SD colorimetric cholesterol concentration for the CEH-CO-POD-DAOS method (5.35 Ϯ 1.47 mmol/L); r ϭ 0.999; S y͉x ϭ 0.065 mmol/L; slope ϭ 0.989 (95% confidence interval, 0.977-1.001); intercept ϭ Ϫ0.048 (95% confidence interval, Ϫ0.117 to 0.022). There was good agreement between the results from the present method and each of the two reference methods.
Discussion
We report a new method for cholesterol determination using CDH from Nocardia sp. The characteristics of the enzyme used have been reported previously (11, 12 ) . The substrate specificity of the CDH used in this report is 100% for cholesterol, 52% for ␤-sitosterol, 50% for ergosterol, 30% for stigmasterol, and 14% for pregnenolone. Other physiological hormones, dehydroepiandrosterone, and testosterone are not substrates. The substrate specificity of CDH is similar or superior to that of CO, which is used in current commercial cholesterol assays (12, 13 ) .
The optimal pH for CDH is Ͼ10.0. The K m values for cholesterol and ␤-NAD ϩ are 0.15 and 0.23 mmol/L, respectively. The reaction is reversible. For this reason, a simple endpoint assay for cholesterol using CDH is impractical. Flegg (14 ) reported an assay system for serum cholesterol that detected the cholest-4-ene-3-one produced by the CDH reaction at 240 nm. However, this method required a long incubation time, as long as 2 h, and was not amenable to automation. We added hydrazine monohydrate to the reaction mixture to trap cholest-4-ene-3-one, similar to the phenylhydrazine reaction used to produce osazone from aldose (15 ) . Although the optimal pH of CDH is Ͼ10.0, the addition of hydrazine makes it possible to carry out the analysis at pH 8.0. The addition of hydrazine to the reaction drives the reaction to completion, and the endpoint is achieved within 3 min. The CEH-CDH method for determining serum cholesterol has several advantages over traditional methods: rapidity, simplicity, and no interference from various reductants, bilirubin, ascorbic acid, or reduced glutathione. Moreover, because the amount of ␤-NADH formed is equivalent to the amount of cholesterol, the concentration of cholesterol in serum can be estimated from a factor calculated from the measured molar absorptivity of ␤-NADH calibrated by that in the Standard Reference Material. This method has excellent accuracy, imprecision, linearity, and correlation with the ALBK and CHE-CO-POD-DAOS methods.
In conclusion, this new CDH method is an accurate, simple, and automatable method for the quantitative analysis of cholesterol.
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